In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead acquires NeXstar for $550mm in all-stock deal

Executive Summary

Gilead Sciences (antiviral biotech) will acquire NeXstar Pharmaceuticals (oncology biotech) for an estimated $550mm in a stock-swap pooling of interests. Each NeXstar share of common stock will be exchanged for 0.425 Gilead common stock.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Liposomes
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies